Trial Profile
A phase II study of everolimus in combination with imatinib in metastatic melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Dec 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Imatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 21 Dec 2013 Last chechked against ClinicalTrials.gov
- 27 Feb 2007 New trial record.